COGNITION THERAPEUTICS INC
CGTXNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $0.55 β $1.81
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 95.1M
- Next Earnings
- 2027-03-25
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -3.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.17
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +91.5%
COGNITION THERAPEUTICS INC
CGTXAbout COGNITION THERAPEUTICS INC
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathiesβa category of diseases encompassing DLB and Parkinson's diseaseβand CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
- Efficient screening processes may reduce participant and site burden in clinical trials - PURCHASE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a cli

What Makes Cognition Therapeutics (CGTX) a New Buy Stock
Cognition Therapeutics (CGTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
PURCHASE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc.Β (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the βCompanyβ or βCognitionβ),

Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript

Cognition Therapeutics Q3 Earnings Call Highlights
Cognition Therapeutics NASDAQ: CGTX is preparing a Phase III trial of its experimental drug zervimesine in dementia with Lewy bodies after reaching alignment with the U.S. Food and Drug Administration on a planned regist

Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
PURCHASE, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders (the βCompanyβ or βCognitionβ),